EXTL2

Summary

EXTL2 (exostosin like glycosyltransferase 2, HGNC:3516) is a protein-coding gene on chromosome 1p21.2, encoding Exostosin-like 2 (Q9UBQ6). Glycosyltransferase required for the biosynthesis of heparan-sulfate and responsible for the alternating addition of beta-1-4-linked glucuronic acid (GlcA) and alpha-1-4-linked N-acetylglucosamine (GlcNAc) units to nascent heparan sulfate chains.

Enables alpha-1,4-N-acetylgalactosaminyltransferase activity and glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity. Involved in N-acetylglucosamine metabolic process and UDP-N-acetylgalactosamine metabolic process. Located in cytosol; endoplasmic reticulum; and nucleoplasm.

Source: NCBI Gene 2135 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 39 total
• MANE Select transcript: NM_001033025

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3516
Approved symbol	EXTL2
Name	exostosin like glycosyltransferase 2
Location	1p21.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000162694
Ensembl biotype	protein_coding
OMIM	602411
Entrez	2135

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 17 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000370113, ENST00000370114, ENST00000416479, ENST00000450240, ENST00000480774, ENST00000494907, ENST00000535414, ENST00000886538, ENST00000886539, ENST00000886540, ENST00000886541, ENST00000886542, ENST00000886544, ENST00000886545, ENST00000886546, ENST00000886547, ENST00000939947, ENST00000939948, ENST00000939949

RefSeq mRNA: 5 — MANE Select: NM_001033025 NM_001033025, NM_001261440, NM_001261441, NM_001261442, NM_001439

CCDS: CCDS72831, CCDS775

Canonical transcript exons

ENST00000370114 — 5 exons

Exon	Start	End
ENSE00001067761	100876794	100876864
ENSE00001067762	100894633	100894842
ENSE00003641584	100888753	100888828
ENSE00003717947	100877476	100877903
ENSE00003848257	100872391	100874430

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 97.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.8832 / max 250.4997, expressed in 1622 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13530	8.9486	1476
13529	3.7536	1238
13531	1.1344	643
13527	0.7798	444
13528	0.2668	116

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	97.45	gold quality
periodontal ligament	UBERON:0008266	92.93	gold quality
postcentral gyrus	UBERON:0002581	92.07	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.80	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.77	gold quality
ventricular zone	UBERON:0003053	90.70	gold quality
right adrenal gland cortex	UBERON:0035827	90.68	gold quality
right adrenal gland	UBERON:0001233	90.40	gold quality
parietal lobe	UBERON:0001872	90.10	gold quality
superior frontal gyrus	UBERON:0002661	89.98	gold quality
left adrenal gland	UBERON:0001234	89.85	gold quality
left adrenal gland cortex	UBERON:0035825	89.74	gold quality
stromal cell of endometrium	CL:0002255	89.71	gold quality
adrenal cortex	UBERON:0001235	89.63	gold quality
Brodmann (1909) area 10	UBERON:0013541	89.50	gold quality
adrenal gland	UBERON:0002369	89.48	gold quality
embryo	UBERON:0000922	89.26	gold quality
placenta	UBERON:0001987	89.15	gold quality
orbitofrontal cortex	UBERON:0004167	88.89	gold quality
prefrontal cortex	UBERON:0000451	88.85	gold quality
choroid plexus epithelium	UBERON:0003911	88.52	gold quality
right uterine tube	UBERON:0001302	88.24	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.24	gold quality
tibia	UBERON:0000979	88.21	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.17	gold quality
caudate nucleus	UBERON:0001873	88.16	gold quality
ganglionic eminence	UBERON:0004023	88.16	gold quality
primary visual cortex	UBERON:0002436	88.04	gold quality
frontal cortex	UBERON:0001870	87.75	gold quality
cortical plate	UBERON:0005343	87.66	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	121.83
E-ANND-3	yes	8.64
E-MTAB-6524	no	136.04

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

92 targeting EXTL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-1193	100.00	65.93	529
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6844	99.82	70.69	2423

Literature-anchored findings (GeneRIF, showing 6)

• donor binding appears to undergo two distinct steps, beginning with the N-acetyl group expelling water from the donor- enzyme complex into the bulk solvent followed by positioning of the donor into the binding site for interactions with the enzyme (PMID:15831490)
• Lysosomal glycosaminoglycan levels in mucopolysaccharidosis are reduced by EXTL2 gene silencing. (PMID:19690583)
• EXTL2 functions to suppress GAG biosynthesis that is enhanced by a xylose kinase and the EXTL2-dependent mechanism that regulates GAG biosynthesis might be a “quality control system” for proteoglycans (PMID:23395820)
• Altered Expression of Aggrecan, FAM20B, B3GALT6, and EXTL2 in Patients with Osteoarthritis and Kashin-Beck Disease. (PMID:32517548)
• The glycosyltransferase EXTL2 promotes proteoglycan deposition and injurious neuroinflammation following demyelination. (PMID:32703234)
• Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion. (PMID:36181793)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	extl2	ENSDARG00000063191
mus_musculus	Extl2	ENSMUSG00000027963
rattus_norvegicus	Extl2	ENSRNOG00000014323

Paralogs (4): EXTL3 (ENSG00000012232), EXT2 (ENSG00000151348), EXTL1 (ENSG00000158008), EXT1 (ENSG00000182197)

Protein

Protein identifiers

Exostosin-like 2 — Q9UBQ6 (reviewed: Q9UBQ6)

Alternative names: Alpha-1,4-N-acetylhexosaminyltransferase EXTL2, Alpha-GalNAcT EXTL2, EXT-related protein 2, Glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase

All UniProt accessions (5): C9IYF5, C9JEG3, Q9UBQ6, F5GZK1, Q8N8F1

UniProt curated annotations — full annotation on UniProt →

Function. Glycosyltransferase required for the biosynthesis of heparan-sulfate and responsible for the alternating addition of beta-1-4-linked glucuronic acid (GlcA) and alpha-1-4-linked N-acetylglucosamine (GlcNAc) units to nascent heparan sulfate chains.

Subcellular location. Endoplasmic reticulum membrane Secreted.

Tissue specificity. Ubiquitous.

Post-translational modifications. The soluble form derives from the membrane form by proteolytic processing.

Pathway. Glycan metabolism; heparan sulfate biosynthesis.

Similarity. Belongs to the glycosyltransferase 47 family.

RefSeq proteins (5): NP_001028197, NP_001248369, NP_001248370, NP_001248371, NP_001430 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015338	GT64_dom	Domain
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily
IPR052427	Glycosyltrans_GT2/GT47	Family

Pfam: PF09258

Enzyme classification (BRENDA):

• EC 2.4.1.223 — glucuronosyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase (BRENDA: 5 organisms, 17 substrates, 1 inhibitors, 0 Km, 0 kcat entries)

Catalyzed reactions (Rhea), 1 shown:

• 3-O-(beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = 3-O-(alpha-D-GlcNAc-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl)-L-seryl-[protein] + UDP + H(+) (RHEA:16221)

UniProt features (31 total): binding site 22, chain 2, topological domain 2, site 1, glycosylation site 1, transmembrane region 1, disulfide bond 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBQ6-F1	89.05	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 53–54 (cleavage); 245

Ligand- & substrate-binding residues (22): 100; 100; 129; 129; 134; 134; 150; 150; 151; 151; 152; 152 …

Disulfide bonds (1): 243–296

Glycosylation sites (1): 74

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2022928	HS-GAG biosynthesis
R-HSA-381038	XBP1(S) activates chaperone genes

MSigDB gene sets: 225 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, REACTOME_UNFOLDED_PROTEIN_RESPONSE_UPR, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, RORA1_01, AAGCCAT_MIR135A_MIR135B, GEORGES_CELL_CYCLE_MIR192_TARGETS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, TGACCTY_ERR1_Q2, BILD_SRC_ONCOGENIC_SIGNATURE, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, MODULE_205, BRN2_01, GOBP_HEPARAN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS

GO Biological Process (4): N-acetylglucosamine metabolic process (GO:0006044), heparan sulfate proteoglycan biosynthetic process (GO:0015012), UDP-N-acetylgalactosamine metabolic process (GO:0019276), carbohydrate derivative metabolic process (GO:1901135)

GO Molecular Function (10): glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity (GO:0001888), glycosaminoglycan binding (GO:0005539), manganese ion binding (GO:0030145), alpha-1,4-N-acetylgalactosaminyltransferase activity (GO:0035248), glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase activity (GO:0047237), protein binding (GO:0005515), acetylglucosaminyltransferase activity (GO:0008375), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), metal ion binding (GO:0046872)

GO Cellular Component (7): Golgi membrane (GO:0000139), extracellular region (GO:0005576), nucleoplasm (GO:0005654), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Heparan sulfate/heparin (HS-GAG) metabolism	1
IRE1alpha activates chaperones	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
amino sugar metabolic process	2
acetylgalactosaminyltransferase activity	2
cytoplasm	2
proteoglycan biosynthetic process	1
heparan sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
nucleotide-sugar metabolic process	1
metabolic process	1
acetylglucosaminyltransferase activity	1
carbohydrate derivative binding	1
transition metal ion binding	1
binding	1
UDP-glycosyltransferase activity	1
hexosyltransferase activity	1
catalytic activity	1
transferase activity	1
cation binding	1
Golgi apparatus	1
bounding membrane of organelle	1
nuclear lumen	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1

Protein interactions and networks

STRING

590 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EXTL2	FAM20B	O75063	702
EXTL2	XYLT1	Q86Y38	669
EXTL2	XYLT2	Q9H1B5	653
EXTL2	EXT1	Q16394	642
EXTL2	B4GALT7	Q9UBV7	622
EXTL2	HS2ST1	Q7LGA3	613
EXTL2	CSGALNACT1	Q8TDX6	598
EXTL2	B3GALT6	Q96L58	596
EXTL2	B3GAT3	O94766	593
EXTL2	CSGALNACT2	Q8N6G5	582
EXTL2	PXYLP1	Q8TE99	578
EXTL2	CCDC188	H7C350	578
EXTL2	NDST2	P52849	577
EXTL2	NDST1	P52848	569
EXTL2	GLCE	O94923	569

IntAct

88 interactions, top by confidence:

A	B	Type	Score
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
EXTL2	GFAP	psi-mi:“MI:0915”(physical association)	0.560
EXTL2	JPH3	psi-mi:“MI:0915”(physical association)	0.560
EXTL2	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
EXTL2		psi-mi:“MI:0915”(physical association)	0.550
SLC39A5	TMEM223	psi-mi:“MI:0914”(association)	0.530
IPPK	TMEM223	psi-mi:“MI:0914”(association)	0.530
MGAT4C	GXYLT2	psi-mi:“MI:0914”(association)	0.530
KCNA10	GAPDHS	psi-mi:“MI:0914”(association)	0.530
SPPL2B	UQCRQ	psi-mi:“MI:0914”(association)	0.530
SCN3B	ABCC5	psi-mi:“MI:0914”(association)	0.530
AOC3	AOC2	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
CSGALNACT2	GOLIM4	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
CHRNA4	FZD6	psi-mi:“MI:0914”(association)	0.530
CSGALNACT2	TPST1	psi-mi:“MI:0914”(association)	0.530
GJC1	EXTL2	psi-mi:“MI:0915”(physical association)	0.400
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (70): EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS), EXTL2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1S6M251, A8Y1P7, H0ZAB5, L7YAI7, O43286, O43505, O60513, O60909, O61394, O61397, O88419, P08037, P15291, P15535, P34548, P34678, P70419, Q09323, Q09363, Q14435, Q3YL68, Q5EA01, Q5EA87, Q5QQ54, Q5QQ55, Q5R4S2, Q66HH1, Q6P768, Q6WV17, Q6WV20, Q7K755, Q80WN7, Q80WN8, Q80WN9, Q8BWP8, Q8I136, Q8IA42, Q8MV48, Q8MVS5, Q91YY2

Diamond homologs: A5D7I4, A9X1C8, O01704, O77783, P70428, P97464, Q16394, Q33AH8, Q5IGR6, Q5IGR7, Q5IGR8, Q5RBC3, Q84WB7, Q92935, Q93063, Q9C975, Q9ES89, Q9JK82, Q9JKV7, Q9LY62, Q9SSE8, Q9UBQ6, Q9V730, Q9XZ08, Q9Y169, A2Y6Z7, O01705, O43909, Q3E9A4, Q3EAR7, Q53WK1, Q94AA9, Q9WVL6, Q6NMM8, A9RGD8, Q6H4N0, Q7XLG3, Q8S1X7, Q8S1X8, Q8S1X9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

39 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1197 predictions. Top by Δscore:

Variant	Effect	Δscore
1:100874428:TTG:T	acceptor_gain	1.0000
1:100874429:TG:T	acceptor_gain	1.0000
1:100874431:C:CC	acceptor_gain	1.0000
1:100876860:CACTG:C	acceptor_gain	1.0000
1:100876862:CTG:C	acceptor_gain	1.0000
1:100888884:T:C	acceptor_gain	1.0000
1:100874426:AATTG:A	acceptor_gain	0.9900
1:100874429:TGCTG:T	acceptor_loss	0.9900
1:100874430:GCTG:G	acceptor_loss	0.9900
1:100874431:CT:C	acceptor_loss	0.9900
1:100876865:C:CC	acceptor_gain	0.9900
1:100888829:C:CC	acceptor_gain	0.9900
1:100888884:T:TC	acceptor_gain	0.9900
1:100894627:CCTTA:C	donor_loss	0.9900
1:100894628:CTTAC:C	donor_loss	0.9900
1:100894629:TTA:T	donor_loss	0.9900
1:100894630:TA:T	donor_loss	0.9900
1:100894631:A:T	donor_loss	0.9900
1:100894632:C:CG	donor_loss	0.9900
1:100874427:ATTG:A	acceptor_gain	0.9800
1:100876188:T:C	acceptor_gain	0.9800
1:100876863:TG:T	acceptor_gain	0.9800
1:100877732:G:A	donor_gain	0.9800
1:100877909:G:GC	acceptor_gain	0.9800
1:100889497:A:C	donor_gain	0.9800
1:100891568:T:TA	donor_gain	0.9800
1:100875847:T:TA	donor_gain	0.9700
1:100876788:CATT:C	donor_loss	0.9700
1:100876789:ATTA:A	donor_loss	0.9700
1:100876790:TTAC:T	donor_loss	0.9700

AlphaMissense

2194 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:100876849:T:A	D150V	0.998
1:100874047:A:C	C296W	0.997
1:100874206:A:C	C243W	0.997
1:100874408:C:T	G176E	0.997
1:100877614:A:G	W99R	0.997
1:100877614:A:T	W99R	0.997
1:100874201:T:A	D245V	0.996
1:100877685:C:G	R75T	0.996
1:100874048:C:T	C296Y	0.995
1:100874207:C:T	C243Y	0.995
1:100877684:T:A	R75S	0.995
1:100877684:T:G	R75S	0.995
1:100877685:C:A	R75I	0.995
1:100874036:A:G	L300P	0.994
1:100874056:C:A	R293S	0.994
1:100874056:C:G	R293S	0.994
1:100874057:C:G	R293T	0.994
1:100874188:A:C	N249K	0.994
1:100874188:A:T	N249K	0.994
1:100874201:T:G	D245A	0.994
1:100874208:A:G	C243R	0.994
1:100874209:G:C	N242K	0.994
1:100874209:G:T	N242K	0.994
1:100874309:G:A	S209F	0.994
1:100876847:C:G	D151H	0.994
1:100877609:G:C	N100K	0.994
1:100877609:G:T	N100K	0.994
1:100877619:A:T	V97E	0.994
1:100874048:C:G	C296S	0.993
1:100874049:A:G	C296R	0.993

dbSNP variants (sampled 300 via entrez): RS1000057002 (1:100872452 A>T), RS1000065415 (1:100896758 A>G), RS1000095794 (1:100877000 G>C), RS1000115193 (1:100876671 C>T), RS1000890729 (1:100890305 G>C), RS1000940768 (1:100890691 T>C), RS1000961585 (1:100884173 C>T), RS1001020858 (1:100896135 T>C,G), RS1001348364 (1:100890831 A>G), RS1002039319 (1:100894787 C>G,T), RS1002242561 (1:100888311 T>A), RS1002259620 (1:100881880 C>A), RS1002445194 (1:100878664 G>A), RS1002507816 (1:100872135 T>C), RS1002839559 (1:100875338 G>C)

Disease associations

OMIM: gene MIM:602411 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001198_20	Multiple sclerosis	4.000000e-08
GCST001198_77	Multiple sclerosis	4.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
ginger extract	increases expression, decreases reaction, increases abundance	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression, decreases reaction, increases abundance	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Mitoxantrone	affects response to substance	1
Oils, Volatile	increases expression, decreases reaction, increases abundance	1
Quercetin	decreases expression	1
Rotenone	increases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.